Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ALX-009 in Healthy Volunteers and Patients with CF or Non-CF Bronchiectasis
NCT02598999Phase 1Terminated
- Sponsor
- Alaxia
- Start
- Nov 2015
- Primary completion
- Dec 2021
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ALX-009 in cystic fibrosis (CF) and bronchiectasis (4 arms), sponsored by Alaxia. Primary endpoint: Safety and tolerability at Day 14. Started Nov 2015; status: terminated.
02
Drugs
ALX-009
03
Conditions
cystic fibrosis (CF)bronchiectasis
Beyond the preview
Go deeper on NCT02598999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02598999.